Sharekhan has given Buy recommendation for Gland Pharma with a target price of Rs. 4400 in its research report issued on Jul 20, 2021

Sharekhan’s research report on Gland Pharma

Gland reported a strong performance for Q1FY22 and results were ahead of estimates. The sales and PAT reported a growth of 30.5% and 12% YoY respectively. Strong growth in the RoW and India markets, double digit growth in the Core markets and Vaccine led opportunities would be the key growth drivers for company. Strong domain expertise and growth prospects, sturdy earnings track record and strong financials are the key positives for Gland.

Outlook

We retain our Buy recommendation on Gland Pharma (Gland) with a revised PT of Rs. 4,400.

Leave a Reply

Your email address will not be published. Required fields are marked *